<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781647</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-H0731-203</org_study_id>
    <nct_id>NCT04781647</nct_id>
  </id_info>
  <brief_title>A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection</brief_title>
  <official_title>A Randomized Phase 2a, Multicenter, Open-label Study Evaluating ABI-H0731-Containing Regimens in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, antiviral activity, and pharmacokinetics&#xD;
      of ABI-H0731 in combination with entecavir (ETV) and with ETV plus pegylated-interferon alpha&#xD;
      (Peg-IFNα) in Chinese participants with chronic hepatitis B virus infection (cHBV)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with an Adverse Event</measure>
    <time_frame>Up to 60 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Premature Discontinuation of Treatment</measure>
    <time_frame>Up to 60 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with a Laboratory Abnormality</measure>
    <time_frame>Up to 60 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in log10 HBV pregenomic RNA (pgRNA)</measure>
    <time_frame>Baseline and at pre-specified time points up to 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in log10 HBV DNA</measure>
    <time_frame>Baseline and at pre-specified time points up to 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in log10 Serum Hepatitis B 'e' Antigen (HBeAg)</measure>
    <time_frame>Baseline and at pre-specified time points up to 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in log10 Serum Hepatitis B Core-related Antigen (HBcrAg)</measure>
    <time_frame>Baseline and at pre-specified time points up to 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in log10 Serum Hepatitis B Surface Antigen (HBsAg)</measure>
    <time_frame>Baseline and at pre-specified time points up to 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Normalized Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline and at pre-specified time points up to 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of ABI-H0731</measure>
    <time_frame>Predose on Day 1, Week 4, and Week 24 and at pre-specified time points postdose up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HBV Variants with Reduced Susceptibility to ABI-H0731</measure>
    <time_frame>Pre-specified time points up to 60 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>ABI-H0731 + ETV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with cHBV will receive ABI-H0731 with ETV for 48 weeks, followed by ETV alone for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABI-H0731 + ETV + Peg-IFNα</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cHBV will receive ABI-H0731 with ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETV + Peg-IFNα</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with cHBV will receive ETV and Peg-IFNα for 24 weeks, followed by ABI-H0731 with ETV for 24 weeks, followed by ETV alone for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-H0731</intervention_name>
    <description>Participants will receive ABI-H0731 300 mg tablets orally once daily</description>
    <arm_group_label>ABI-H0731 + ETV</arm_group_label>
    <arm_group_label>ABI-H0731 + ETV + Peg-IFNα</arm_group_label>
    <other_name>Vebicorvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETV</intervention_name>
    <description>Participants will receive ETV 0.5 mg tablets orally once daily</description>
    <arm_group_label>ABI-H0731 + ETV</arm_group_label>
    <arm_group_label>ABI-H0731 + ETV + Peg-IFNα</arm_group_label>
    <arm_group_label>ETV + Peg-IFNα</arm_group_label>
    <other_name>Entecavir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peg-IFNα</intervention_name>
    <description>Participants will receive Peg-IFNα with a starting dose of 180 µg solution by subcutaneous injection once weekly</description>
    <arm_group_label>ABI-H0731 + ETV + Peg-IFNα</arm_group_label>
    <arm_group_label>ETV + Peg-IFNα</arm_group_label>
    <other_name>Pegylated-interferon Alpha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) 18 to 36 kg/m^2 and a minimum body weight of 45 kg (inclusive)&#xD;
&#xD;
          -  Female subjects must be non-pregnant and have a negative serum pregnancy test&#xD;
&#xD;
          -  Chronic hepatitis B infection, defined as HBV infection for ≥6 months documented, for&#xD;
             example, by at least 2 measurements of HBsAg positivity and/or detectable HBV DNA ≥6&#xD;
             months apart (inclusive of Screening). For subjects without clear documentation of&#xD;
             CHB, serum immunoglobulin M (IgM) antibody to the HBV core antigen (HBcAb) must be&#xD;
             negative at Screening to exclude acute HBV infection.&#xD;
&#xD;
          -  HBeAg positive with HBV DNA ≥2 × 10^4 IU/mL at Screening&#xD;
&#xD;
          -  Lack of cirrhosis or advanced liver disease&#xD;
&#xD;
          -  A candidate for interferon-based therapy&#xD;
&#xD;
          -  Agreement to comply with protocol-specified contraceptive requirements&#xD;
&#xD;
          -  Agreement to abstain from alcohol abuse and the use of illicit substances from&#xD;
             Screening through the duration of the study&#xD;
&#xD;
          -  In good general health, except for cHBV, in the opinion of the Investigator&#xD;
&#xD;
          -  Able to take oral medication and be willing to receive subcutaneous injections of&#xD;
             Peg-IFNα.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or prior treatment for CHB with&#xD;
&#xD;
               -  A nucleos(t)ide reverse transcriptase inhibitor of the HBV polymerase (NrtI)&#xD;
                  (ETV, tenofovir disoproxil fumarate or tenofovir alafenamide) for &gt;4 weeks at any&#xD;
                  time. Note, NrtI treatment of ≤4 weeks duration cannot be within 6 months prior&#xD;
                  to Screening&#xD;
&#xD;
               -  Interferon-based therapy within 6 months prior to Screening&#xD;
&#xD;
               -  Liver-protecting and/or ALT-lowering treatment including traditional Chinese&#xD;
                  medicine within 1 month of Screening&#xD;
&#xD;
               -  Lamivudine, telbivudine or adefovir (of any duration)&#xD;
&#xD;
               -  Previous treatment with siRNA within 9 months prior to Screening&#xD;
&#xD;
               -  HBV core inhibitors (any duration)&#xD;
&#xD;
               -  Previous treatment with any other investigational agent for HBV infection within&#xD;
                  6 months prior to Screening&#xD;
&#xD;
          -  Co-infection with human immunodeficiency virus (HIV), hepatitis A virus (HAV)&#xD;
             hepatitis C virus (HCV), hepatitis E virus (HEV), or hepatitis D virus (HDV)&#xD;
&#xD;
          -  Females who are lactating, or wish to become pregnant during the course of the study&#xD;
&#xD;
          -  History or evidence of advanced liver disease or hepatic decompensation at any time&#xD;
             prior to, or at the time of Screening&#xD;
&#xD;
          -  History of persistent alcohol abuse or illicit drug abuse within 3 years prior to&#xD;
             Screening&#xD;
&#xD;
          -  Clinically significant psychiatric disease, including severe depression, history of&#xD;
             suicidal ideation or suicide attempt&#xD;
&#xD;
          -  Clinically significant cardiac disease including poorly controlled or unstable&#xD;
             hypertension; pulmonary disease; chronic or recurrent renal or urinary tract disease;&#xD;
             liver disease other than cHBV; endocrine disorder; autoimmune disorder; poorly&#xD;
             controlled diabetes mellitus; neuromuscular, musculoskeletal, or mucocutaneous&#xD;
             conditions requiring frequent treatment; seizure disorders requiring treatment;&#xD;
             ongoing infection or other medical conditions requiring frequent medical management;&#xD;
             or pharmacologic or surgical treatment that, in the opinion of the Investigator or the&#xD;
             Sponsor, makes the subject unsuitable for study participation&#xD;
&#xD;
          -  History of hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  History of malignancy other than HCC unless the subject's malignancy has been in&#xD;
             complete remission off chemotherapy and without additional medical or surgical&#xD;
             interventions during the 3 years before Screening&#xD;
&#xD;
          -  History or presence at Screening of electrocardiogram (ECG) abnormalities deemed&#xD;
             clinically significant, in the opinion of the Investigator&#xD;
&#xD;
          -  History of hypersensitivity or idiosyncratic reaction to any components or excipients&#xD;
             of the investigational drug&#xD;
&#xD;
          -  History of any significant food or drug-related allergic reactions such as,&#xD;
             anaphylaxis or Stevens-Johnson syndrome&#xD;
&#xD;
          -  Exclusionary laboratory results at Screening:&#xD;
&#xD;
               -  Hemoglobin &lt;12g/dL for males or &lt;11g/dL for females&#xD;
&#xD;
               -  Platelet count &lt;100,000/mm^3&#xD;
&#xD;
               -  White blood cell count &lt;2,500/mm^3&#xD;
&#xD;
               -  Absolute neutrophil count &lt;1,500/mm^3&#xD;
&#xD;
               -  Albumin &lt;lower limit of normal&#xD;
&#xD;
               -  History of thyroid disease poorly controlled on prescribed medications, with&#xD;
                  thyroid-stimulating hormone (TSH), free triiodothyronine or free thyroxine (T4)&#xD;
                  outside the normal limits&#xD;
&#xD;
               -  Total bilirubin &gt;1.2 × upper limit of normal (ULN)&#xD;
&#xD;
               -  Direct bilirubin &gt;1.2 × ULN&#xD;
&#xD;
               -  ALT ≤1 x ULN or ≥10 × ULN&#xD;
&#xD;
               -  Serum alpha fetoprotein (AFP) ≥100 ng/mL. If AFP at Screening is &gt;ULN but &lt;100&#xD;
                  ng/mL, the participant is eligible if a hepatic imaging trial prior to initiation&#xD;
                  of study drug reveals no lesions indicative of possible HCC.&#xD;
&#xD;
               -  International Normalized Ratio &gt;1.5 × ULN unless on a stable anticoagulant&#xD;
                  regimen&#xD;
&#xD;
               -  Glomerular filtration rate &lt;60 mL/min/1.73 m^2 by Chronic Kidney Disease&#xD;
                  Epidemiology Collaboration equation&#xD;
&#xD;
               -  Serum creatinine &gt;1.5 x ULN&#xD;
&#xD;
               -  Any other laboratory abnormality deemed clinically significant by the Sponsor or&#xD;
                  the Investigator.&#xD;
&#xD;
          -  Subjects receiving prohibited concomitant medications or medications that should be&#xD;
             avoided within 7 days or 5 half-lives (if known), whichever is longer, prior to&#xD;
             administration of the first dose of study drug (Day 1) and for the duration of the&#xD;
             study period. Please refer to Exclusion Criterion #1 for criteria regarding liver&#xD;
             protecting and/or ALT lowering agents&#xD;
&#xD;
          -  Participation in another clinical study of any non-HBV-related drug or device whereby&#xD;
             the last investigational drug/device administration is within 60 days or 5 half-lives&#xD;
             prior to the first study drug administration (Day 1), whichever is longer.&#xD;
&#xD;
          -  Subjects who have received, in the previous 4 weeks, a treatment likely to alter the&#xD;
             immune response (intravenous immunoglobulins, blood-derived products, or high-dose&#xD;
             steroids, or other immunosuppressants).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace Wang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assembly Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Assembly Biosciences</last_name>
    <phone>833-509-4583</phone>
    <email>clinicaltrials@assemblybio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, First Military Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>8th Affiliated Hospital of Guangzhou</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jilin University First Hospital</name>
      <address>
        <city>Chang chun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital, College of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheng</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cHBV</keyword>
  <keyword>HBV</keyword>
  <keyword>vebicorvir</keyword>
  <keyword>VBR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

